INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Key facts

Sponsor

Incyte Biosciences International Sàrl

Principal Investigator

Nawel Bourayou, MD

Incyte Corporation

Intervention

INCAGN01876(biological)

Eligibility

18-99 years · All sexes

Timeline

2023 – 2025

Study locations (17)

• Uab Medicine-the Kirklin Clinic, Birmingham, Alabama, United States
• University of California San Diego Medical Center, Moores Cancer Center, La Jolla, California, United States
• Stanford University, Palo Alto, California, United States
• Toi Clinical Research, Whittier, California, United States
• University of Chicago, Chicago, Illinois, United States
• University of Kansas Cancer Center, Westwood, Kansas, United States
• Norton Cancer Institute, Louisville, Kentucky, United States
• University of Maryland-Greenebaum Cancer Center, Baltimore, Maryland, United States
• Dana Farber Cancer Institute, Boston, Massachusetts, United States
• Karmanos Cancer Institute, Detroit, Michigan, United States
• John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
• Mount Sinai Prime, New York, New York, United States
• University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States
• Providence Portland Med. Ctr, Portland, Oregon, United States
• Md Anderson Cancer Center, Houston, Texas, United States
• +2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of head and neck

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07333274
  Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
  Shandong Cancer Hospital and Institute
• RECRUITINGPHASE3NCT07026474
  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
  Universität des Saarlandes
• RECRUITINGPHASE1NCT07182149
  A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
  Normunity AccelCo, Inc.
• RECRUITINGNANCT07203911
  Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
  Tobias Todsen
• RECRUITINGNANCT07180901
  Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer
  Centre hospitalier de l'Université de Montréal (CHUM)
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415
  Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
  China Medical University Hospital
• RECRUITINGPHASE2NCT07088211
  Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
• RECRUITINGPHASE2NCT07040956
  A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
  West China Hospital

See all trials for Squamous cell carcinoma of head and neck →